Specifically, using small molecule inhibitors combined with immune-modulating antibodies (including GITR agonists) could be the key to decreasing the immune threshold for anti-tumor effects, resulting in long-term anti-tumor immune effects. The gene discussed is TNFRSF18; the disease is neoplasm.